Taxotere, Docetaxel Newswire (Page 10)

Taxotere, Docetaxel Newswire (Page 10)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 10)

Results 181 - 200 of 3,252 in Taxotere, Docetaxel (generic)

  1. Bristol-Myers Squibb Release: Two-Year Overall Survival Data From Two ...Read the original story

    May 18, 2016 | BioSpace

    Bristol-Myers Squibb Company announced today two-year overall survival data from two pivotal Phase 3 studies evaluating Opdivo versus docetaxel in previously treated metastatic non-small cell lung cancer . Opdivo continued to demonstrate improved overall survival , the primary endpoint for both studies, at the landmark two-year time point.

    Comment?

  2. Oncolytics Biotech Inc. Reports Preliminary Data from Randomized...Read the original story

    May 19, 2016 | Canada NewsWire

    Patients with non-squamous cell histology were treated with REOLYSIN given in combination with pemetrexed versus pemetrexed alone . Patients with squamous cell histology were treated with REOLYSIN given in combination with docetaxel versus docetaxel alone .

    Comment?

  3. Studies suggest drugs for advanced lung, skin cancers extend patients' livesRead the original story w/Photo

    May 19, 2016 | Fox News

    Two new drugs that help the immune system fight some of the deadliest cancers are helping patients live years longer than older treatments, according to clinical trial results that should further boost confidence in this approach to oncology. Merck & Co showed that its Keytruda drug helped many patients with advanced melanoma survive at least three years, while Bristol-Myers demonstrated that Opdivo can prolong life for a significant number of patients with advanced lung cancer by at least two years.

    Comment?

  4. Bayer To Showcase Latest Oncology Research At ASCO 2016Read the original story w/Photo

    May 18, 2016 | BioSpace

    The data represent clinical research on Bayer's oncology products, as well as continued investigation of Xofigo injection in other areas of metastatic castration-resistant prostate cancer . , M.D., Bayer's senior vice president and head of medical affairs for the Americas.

    Comment?

  5. Pretreatment neutrophil-to-lymphocyte ratio is correlated with...Read the original story w/Photo

    May 19, 2016 | BioMed Central

    A high neutrophil-to-lymphocyte ratio may be related to increased mortality in patients with lung, colorectal, stomach, liver, and pancreatic cancer. To date, the utility of NLR to predict the response to neoadjuvant chemotherapy has not been studied.

    Comment?

  6. Two-Year Overall Survival Data from Two Pivotal Opdivo (nivolumab)...Read the original story w/Photo

    May 18, 2016 | Freshnews

    Two-Year Overall Survival Data from Two Pivotal OpdivoA Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer Opdivo demonstrated an overall survival benefit at the landmark two-year time point versus docetaxel in previously treated advanced non-small cell lung cancer, across histologies Data show benefit with Opdivo in the overall population, with nearly double and triple the patients alive at two years compared to docetaxel Two-Year Overall Survival Data from Two Pivotal Opdivo A Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer Bristol-Myers Squibb Company announced today two-year overall survival data from two pivotal Phase 3 studies evaluating Opdivo versus docetaxel in previously treated metastatic non-small cell lung cancer .

    Comment?

  7. Cerulean to Present at the 2016 ASCO Annual MeetingRead the original story

    May 18, 2016 | Freshnews

    Cerulean Pharma Inc. , a clinical-stage company developing nanoparticle-drug conjugates , announced a scheduled poster presentation on CRLX301 at the American Society of Clinical Oncology Annual Meeting being held June 3-7, 2016, at McCormick Place in Chicago. Title: A Phase 1 Study of CRLX301, a Novel Nanoparticle-Drug Conjugate Containing Docetaxel , in Patients with Refractory Solid Tumors Poster Session : Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics Date and Time : June 5, 2016 8:00-11:30 am CDT Abstract Number : 2526 Poster Board Number : 226 Location: Hall A Summary: CRLX301 is generally well tolerated with hints of antitumor activity, and with differentiated pharmacokinetics compared to DOC.

    Comment?

  8. Merck, Bristol drugs show longer survival for deadly cancersRead the original story

    May 18, 2016 | Reuters

    Two new drugs that help the immune system fight some of the deadliest cancers are helping patients live years longer than older treatments, according to clinical trial results that should further boost confidence in this approach to oncology. Merck & Co showed that its Keytruda drug helped many patients with advanced melanoma survive at least three years, while Bristol-Myers demonstrated that Opdivo can prolong life for a significant number of patients with advanced lung cancer by at least two years.

    Comment?

  9. Bankruptcy filing worries developers of nanoparticle cancer drugsRead the original story w/Photo

    May 18, 2016 | NatureNews

    Not long ago, investors flocked to a firm in Massachusetts that was hailed as the leader in a wave of next-generation nanotechnology companies developing ways to ferry cancer drugs to tumours. But on 2 May, the company - BIND Therapeutics - declared bankruptcy.

    Comment?

  10. BIND Therapeutics Inc (BIND) Upgraded at Zacks Investment ResearchRead the original story w/Photo

    May 17, 2016 | AmericanBankingNews.com

    The firm presently has a $0.50 target price on the stock. Zacks Investment Research 's price target suggests a potential upside of 38.89% from the stock's previous close.

    Comment?

  11. Eagle Pharmaceuticals Inc (EGRX) Shares Down 2.8% Following Insider SellingRead the original story w/Photo

    May 17, 2016 | Daily Political

    Eagle Pharmaceuticals Inc fell 2.8% on Tuesday following insider selling activity. The company traded as low as $42.48 and last traded at $42.98, with a volume of 249,670 shares changing hands.

    Comment?

  12. Eagle Pharmaceuticals Inc (EGRX) Major Shareholder Sells $732,145.60 in StockRead the original story w/Photo

    May 17, 2016 | Daily Political

    Eagle Pharmaceuticals Inc major shareholder Proquest Management Llc sold 17,980 shares of the firm's stock in a transaction that occurred on Friday, May 13th. The shares were sold at an average price of $40.72, for a total transaction of $732,145.60.

    Comment?

  13. Genetic biomarker may predict nerve pain side effects associated with prostate cancer treatmentRead the original story w/Photo

    May 16, 2016 | Medical News Today

    New study finds genetic alterations in the VAC14 gene are associated with an increased risk of docetaxel-induced peripheral neuropathy in prostate cancer patients. Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects.

    Comment?

  14. Genetic Biomarker May Predict Nerve Pain Side Effects Associated with ...Read the original story

    May 13, 2016 | Newswise

    Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers from Moffitt Cancer Center report prostate cancer patients who have a variation in the VAC14 gene are more susceptible to a side effect called peripheral neuropathy when treated with the taxane docetaxel.

    Comment?

  15. OncoGenex Reports Financial Results For First Quarter 2016Read the original story

    May 12, 2016 | BioSpace

    Based on current expectations, OncoGenex believes that its cash, cash equivalents, and short-term investments will be sufficient to fund its currently planned operations into the third quarter of 2017. Depending on timing of enrollment or event-driven final analyses, the expected key milestones and activities are as follows: Announcing results from the AFFINITY trial, the phase 3 trial evaluating a survival benefit for custirsen in combination with cabazitaxel as second-line chemotherapy in approximately 630 patients with castrate-resistant prostate cancer.

    Comment?

  16. BeyondSpring Chief Medical Officer Served As Panelist At NewYorkBIORead the original story

    May 12, 2016 | BioSpace

    "In BeyondSpring's Phase II clinical trial, we observed that Plinabulin mitigated Docetaxel-induced grade 4 Neutropenia and its clinical sequelae , improving Docetaxel dose intensity. Therefore, Plinabulin's product profile is attractive, as it can serve as an effective, safe, convenient and cost-effective alternative to G-CSF, including its biosimilars.

    Comment?

  17. Eagle Pharmaceuticals Inc (EGRX) Stock Price Down 5.6% After Analyst DowngradeRead the original story w/Photo

    May 11, 2016 | Daily Political

    Eagle Pharmaceuticals Inc 's share price traded down 5.6% during trading on Wednesday after RBC Capital lowered their price target on the stock from $94.00 to $78.00, MarketBeat reports. RBC Capital currently has an outperform rating on the stock.

    Comment?

  18. Eagle Pharmaceuticals Inc (EGRX) PT Lowered to $78.00 at RBC CapitalRead the original story w/Photo

    May 10, 2016 | AmericanBankingNews.com

    The firm currently has an "outperform" rating on the specialty pharmaceutical company's stock. RBC Capital's price objective would suggest a potential upside of 95.73% from the company's current price.

    Comment?

  19. Halozyme Reports First Quarter 2016 Financial ResultsRead the original story

    May 9, 2016 | BioSpace

    "During the first quarter, we continued to execute against our two-pillar strategy with ongoing clinical studies of PEGPH20 and through growing the value of our ENHANZE , president and chief executive officer. "We made good progress toward our goal of initiating greater than 90 percent of HALO-301 sites by the end of the year and in evaluating the recommended dose to take into the expansion phase of our lung and gastric cancer studies.

    Comment?

  20. Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    May 9, 2016 | Seeking Alpha

    Good morning. My name is Keith, and I will be your conference operator today. At this time, I would like to welcome everyone to the Eagle Pharmaceuticals First Quarter 2016 Earnings Results Conference Call.

    Comment?